Printer Friendly

BERGEN BRUNSWIG CORPORATION REPORTS FOURTH QUARTER AND FISCAL YEAR END RESULTS

 BERGEN BRUNSWIG CORPORATION REPORTS
 FOURTH QUARTER AND FISCAL YEAR END RESULTS
 ORANGE, Calif., Sept. 29 /PRNewswire/ -- Bergen Brunswig Corporation (AMEX: BBC) today reported results for the fourth quarter and fiscal year ended g?ust 31, 1992.
 Net sales and other revenues for the year were a record $5.05 billion, an increase of 18 percent compared to $4.30 billion for fiscal 1991. Net earnings for the 1992 fiscal year were $60.9 million or $1.53 per share, fully diluted. This compared to $64.1 million or $1.44 per share, fully diluted, a year ago.
 Net earnings for the year ended August 31, 1992, included earnings from continuing operations of $53.0 million or $1.36 per fully diluted share compared to $58.1 million or $1.32 per fully diluted share for the similar period last year. The average number of common and common equivalent shares used in the computation of fully diluted earnings per share for the fiscal year ended August 31, 1992 was 45.4 million compared to 50.4 million last year. Earnings from discontinued operations of Commtron Corporation were $7.9 (A) million compared to $6.1 million for the prior year. The company completed the sale of Commtron during the fourth quarter.
 For the fourth quarter ended August 31, 1992, net sales and other revenues from continuing operations reached a record high, increasing 21 percent to $1.34 billion from $1.11 billion for the comparable quarter last year. Net earnings increased 37 percent to $17.7 million compared to $12.9 million in the prior year. Fully diluted earnings per share were $0.46 compared to $0.31 for the similar period a year ago, an increase of approximately 48 percent. Net earnings for the quarter consisted of earnings from continuing operations of $14.9 million or $0.39 per share fully diluted, compared to $11.8 million or $0.29 per share fully diluted in the fourth quarter last year. The average number of common and common equivalent shares used in the computation of fully diluted earnings per share for the quarter was 43.7 million compared to 49.4 million last year. Earnings from discontinued operations were $2.9 (A) million this quarter compared to $1.1 million a year ago.
 Robert E. Martini, chairman and CEO said, "Results for both the fourth quarter and the fiscal year met the company's objectives. Earnings were impacted by the recessionary economic environment especially in California, decreased forward buying opportunities and competitive pricing. However, the company has been able to continue to reduce general operating expenses as a percentage of sales through improved distribution technology."
 "The company accomplished its goal for internal growth and increased market share for the year. External growth objectives were more than exceeded through the acquisition of substantially all of Owens & Minor, Inc.'s pharmaceutical distribution business, and the merger which is currently being completed with Durr-Fillauer Medical, Inc. The major portion of the costs attributable to the Durr-Fillauer merger will be capitalized," Martini added.
 Bergen Brunswig Corporation is one of the nation's largest distributors of prescription pharmaceuticals and other health care products.
 Note (A): Includes gain on disposition of Commtron of $4.0 million.
 BERGEN BRUNSWIG CORPORATION
 Summary of Consolidated Sales and Earnings
 (in thousands except share and per share amounts, unaudited)
 Fourth Quarter Twelve Months
 Periods Ended Aug. 31
 1992 1991 1992 1991
 Net sales and
 other revenues $1,340,871 $1,111,461 $5,048,309 $4,295,397
 Costs and expenses:
 Cost of sales 1,258,781 1,038,192 4,729,038 3,990,618
 Selling, general
 & admin.
 expenses 57,448 54,848 228,857 211,915
 Total costs
 & expenses 1,316,229 1,093,040 4,957,895 4,202,533
 Operating earnings
 from continuing
 operations 24,642 18,421 90,414 92,864
 Net interest expense 976 844 6,944 3,238
 Earnings from continuing
 operations before taxes
 on income 23,666 17,577 83,470 89,626
 Taxes on income from
 continuing operations 8,792 5,783 30,458 31,565
 Earnings from
 continuing operations 14,874 11,794 53,012 58,061
 Earnings (loss) from
 discontinued operations,
 net of taxes
 on income (1,110) 1,136 3,876 6,076
 Gain on disposition
 after taxes 3,976 -- 3,976 --
 Net earnings $17,740 $12,930 $60,864 $64,137
 Fourth Quarter Twelve Months
 Periods Ended August 31
 1992 1991 1992 1991
 Average number of
 common and common
 equivalent shares (A):
 Primary 35,970,542 41,587,227 37,644,849 42,657,359
 Fully Diluted 43,738,033 49,356,216 45,416,860 50,434,056
 Earnings (loss)
 per share (A):
 Primary:
 Continuing operations $.41 $.29 $1.41 $1.36
 Discontinued operations (.03) .02 .10 .14
 Gain on disposition .11 - .11 -
 Net earnings $.49 $.31 $1.62 $1.50
 Fully Diluted:
 Continuing operations $.39 $.29 $1.36 $1.32
 Discontinued operations (.02) .02 .08 .12
 Gain on disposition .09 - .09 -
 Net earnings $.46 $.31 $1.53 $1.44
 NOTE (A): Earnings per common and common equivalent share are based on the weighted average number of shares of Class A common stock outstanding during each period, the assumed conversion of the weighted average number of shares of Class B common stock outstanding during each period and the assumed exercise of employees' stock options. Fully diluted earnings per share assume conversion of the LYONS due 2004 (zero coupon-subordinated) from the issue date of November 16, 1989.
 NOTE (B): Addback to net earnings for fully diluted earnings per share computation: LYONS interest,
 net of tax effect $2,251 $2,191 $8,735 $8,324
 -0- 9/29/92
 /CONTACT: Neil F. Dimick, executive vice president-chief financial officer of Bergen Brunswig, 714-385-4000/
 (BBC) CO: Bergen Brunswig Corporation ST: California IN: MTC SU: ERN


TM -- NY007 -- 4223 09/29/92 08:56 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 29, 1992
Words:980
Previous Article:THE PRICE COMPANY ANNOUNCES FOURTH QUARTER RESULTS FOR FISCAL 1992
Next Article:USAIR OPENS NEW LAGUARDIA TERMINAL
Topics:


Related Articles
BERGEN BRUNSWIG REPORTS FIRST QUARTER RESULTS
BERGEN BRUNSWIG REPORTS SECOND QUARTER AND SIX MONTH RESULTS
BERGEN BRUNSWIG REPORTS THIRD QUARTER AND NINE MONTH RESULTS
BERGEN BRUNSWIG REPORTS THIRD QUARTER AND NINE MONTH RESULTS
BERGEN BRUNSWIG CORP. ANNOUNCES PRELIMINARY EARNINGS AND RESTRUCTURING OF DRUG DISTRIBUTION BUSINESS
BERGEN BRUNSWIG REPORTS FOURTH QUARTER AND YEAR END RESULTS
Bergen Brunswig Medical Corporation and Myriad Ultrasound Systems Announce Distribution Agreement.
DCR Rates Bergen Capital Trust I`s Preferred Securities `BBB`.
DCR Rates Bergen Capital Trust I's Preferred Securities 'BBB'.
Law Offices of Lionel Z. Glancy Continues Lawsuit Against Bergen Brunswig Corporation.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters